Complement-5 Inhibition Deters Progression of Fulminant Hepatitis to Acute Liver Failure in Murine Models

• Published in: Cellular and molecular gastroenterology and hepatology Vol. 11; no. 5; pp. 1351 - 1367
• Main Authors: Kusakabe, Jiro, Hata, Koichiro, Miyauchi, Hidetaka, Tajima, Tetsuya, Wang, Yi, Tamaki, Ichiro, Kawasoe, Junya, Okamura, Yusuke, Zhao, Xiangdong, Okamoto, Tatsuya, Tsuruyama, Tatsuaki, Uemoto, Shinji
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2021; Elsevier
• Subjects: Anaphylatoxin; Animals; Antibodies, Monoclonal - pharmacology; Apoptosis; Complement C5 - antagonists & inhibitors; Complement C5 - immunology; Disease Models, Animal; Disease Progression; Eculizumab; Liver Failure, Acute - etiology; Liver Failure, Acute - pathology; Liver Failure, Acute - prevention & control; Macrophages - drug effects; Macrophages - immunology; Male; Massive Hepatic Necrosis - complications; Membrane Attack Complex (MAC: C5b-9); Mice; Original Research; Tumor Necrosis Factor-alpha - metabolism; Membrane Attack Complex (MAC: C5b-9); D-GalN; Ab; IL; KO; JNK; IgG; ALT; Cyt C; LPS; MAC; mAb; C5; Con-A; TNF-α; Eculizumab; ALF; Anaphylatoxin; C5aR; WT; ssDNA; 8-OHdG; ELISA; HMGB-1

Acute liver failure (ALF) is a life-threatening condition with limited treatment alternatives. ALF pathogenesis seemingly involves the complement system. However, no complement-targeted intervention has been clinically applied. In this study, we aimed to investigate the potential of Complement-5 (C5...